Alembic Pharmaceuticals Limited — Updates, 11-11-2024: Press Release

Alembic Pharmaceuticals has received final approval from the USFDA for its Diltiazem Hydrochloride Extended-Release Capsules in various dosages (120 mg, 180 mg, 240 mg, 300 mg, and 360 mg). This product is therapeutically equivalent to Cardizem CD and is indicated for hypertension and chronic stable angina management. The estimated market size for this medication is approximately $105.3 million for the twelve months ending June 2024. Alembic now holds a total of 218 ANDA approvals from the USFDA.